Venous Embolism of Lower Extremities (Diagnosis)NCT07335341
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
An observational study of Venous Embolism of Lower Extremities (Diagnosis) and Arterial Embolism and Thrombosis, run by Medtronic Endovascular at 6 sites in United States.
Trial summary
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of… Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity
- What is being tested?
- Liberant Thrombectomy System
- Type of treatment
- Medical device
- How many people
- 51 participants
- Where
- 6 sitesUnited States
- Study dates
- 24 Feb 2026to 30 Oct 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The Liberant thrombectomy system is intended for use in adult patients with occluded peripheral arterial and venous vessels.
Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:
- Patient treated is age ≥ 22 years at the time of procedure
- Use of Liberant in accordance with the device labeling within 72 hours of index procedure
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United States6 sites
NewYork-Presbyterian Medical Group Brooklyn
Brooklyn, New York, 11201
Naples Comprehensive Health
Naples, Florida, 34108
Mount Sinai
New York, New York, 10029
Baylor Heart Hospital Of Plano
Plano, Texas, 75093
HonorHealth Heart Care - Vascular - Osborn
Scottsdale, Arizona, 85251
MedStar Health
Washington D.C., District of Columbia, 003329
About this study
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
Read the detailed description
The Liberant Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual case experience following routine utilization of Liberant in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural incidents of risk and evaluate device performance. At least 50 use cases will be collected and aggregated from at least 10 participating HCPs. This data collection is for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.
- Conditions
- Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg
- Being tested
- Liberant Thrombectomy System
- Keywords
- Thrombus in Peripheral Arterial Systems, Thrombectomy, Thrombosis, Venous Thrombosis, Aspiration Thrombectomy, Percutaneous Mechanical Thrombectomy, Arterial Occlusive Diseases, Vascular Diseases, Peripheral Vascular Diseases, Peripheral Arterial Disease, Mechanical Thrombectomy, Aspiration, Liberant Thrombectomy System, adverse events, Excipio, Thrombus in Peripheral Venous Systems
- Medical subject headings
- Disease, Thrombosis, Venous Thrombosis, Peripheral Arterial Disease, Arterial Occlusive Diseases, Vascular Diseases, Peripheral Vascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liberant Thrombectomy SystemDevice
The Liberant thrombectomy system is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of Device related Serious Adverse Event at Index procedure
An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System
Measured: Index Procedure
Rate of technical success at Index procedure
Technical success: Successful introduction, delivery, aspiration of fresh, soft emboli or thrombi, and retrieval of the Liberant per the Instructions for Use (IFU) during the index procedure
Measured: Index procedure
Rate of Procedural Success at Index procedure
Procedure success: Successful removal of fresh, soft emboli or thrombi and restoration of adequate blood flow, inclusive of all endovascular therapies during the index procedure
Measured: Index procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start24 Feb 2026
- Primary completion30 Oct 2026
- Study completion30 Oct 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Venous Embolism of Lower Extremities (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medtronic Endovascular
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- John R Laird Jr, MD, Principal investigator, Medtronic Endovascular
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07335341
- Sponsor's protocol ID
- MDT25034
- Status last verified
- Nov 2026
- First submitted
- 5 Jan 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: No patients will be engaged, and no medical records will be accessed or used. Individual HCP responses for each case will be aggregated into a final report.
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
- ClinicalTrials.gov ID
- NCT07335341
- Acronym / sponsor ID
- MDT25034
- Conditions
- Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg
- Keywords
- Thrombus in Peripheral Arterial Systems, Thrombectomy, Thrombosis, Venous Thrombosis, Aspiration Thrombectomy, Percutaneous Mechanical Thrombectomy, Arterial Occlusive Diseases, Vascular Diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Medtronic EndovascularIndustry (pharma, biotech, devices)
- Study start
- 24 Feb 2026 (actual)
- Primary completion
- 30 Oct 2026 (actual)
- Study completion
- 30 Oct 2026 (actual)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
Detailed description
The Liberant Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual case experience following routine utilization of Liberant in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural incidents of risk and evaluate device performance. At least 50 use cases will be collected and aggregated from at least 10 participating HCPs. This data collection is for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The Liberant thrombectomy system is intended for use in adult patients with occluded peripheral arterial and venous vessels.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liberant Thrombectomy SystemThe Liberant thrombectomy system is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems | Device | – |
Primary outcome
Rate of Device related Serious Adverse Event at Index procedure
Time frame: Index Procedure
An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System
Rate of technical success at Index procedure
Time frame: Index procedure
Technical success: Successful introduction, delivery, aspiration of fresh, soft emboli or thrombi, and retrieval of the Liberant per the Instructions for Use (IFU) during the index procedure
Rate of Procedural Success at Index procedure
Time frame: Index procedure
Procedure success: Successful removal of fresh, soft emboli or thrombi and restoration of adequate blood flow, inclusive of all endovascular therapies during the index procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No. No patients will be engaged, and no medical records will be accessed or used. Individual HCP responses for each case will be aggregated into a final report.
Related trials for Venous Embolism of Lower Extremities (Diagnosis)
RecruitingObservational study
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature
RecruitingObservational study
TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower Limb Trauma Requiring Immobilization
Lower Extremity Injuries, Venous Thromboembolism (VTE)
Recruiting
Delivery and Implementation of a Randomised Crossover Trial on Thrombosis
Hip Fractures, Venous Thromboembolism (VTE)
RecruitingObservational study
Predictive Value of Modified Caprini Score and D-Dimer in Managing Lower Limb Venous Thrombosis in Cardiothoracic Patients
DVT - Deep Vein Thrombosis
Active, not recruiting
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
Venous Thromboses, Venous Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John R Laird Jr, MD principal investigator
Medtronic Endovascular
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Venous Embolism of Lower Extremities (Diagnosis) and Arterial Embolism and Thrombosis, run by Medtronic Endovascular at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of Device related Serious Adverse Event at Index procedure (time frame: Index Procedure). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.